Contact

Harbor Quill Home About Services Clinical Evidence Safety & Risks Law & Policy Contact Harbor Quill / Field Notes Risk · Research · Regulation 01 A cautious primer Ibogaine Supplement A psychoactive substance is not made low-risk by the language of wellness. Here is the evidence-first context for ibogaine, treatment claims, law, and safety. Independent guidance on ibogaine research, risk, and policy. / August 2026 Fig. 01 — Ibogaine is often described in supplement language, but its effects, legal status, and risk profile demand a medical and regulatory frame. Department / Foundations A plant-derived compound with a complex history. Terms matter: ibogaine is not a conventional wellness product, and its possible therapeutic potential remains under study rather than established care. At a glance Ibogaine is a naturally occurring psychoactive alkaloid primarily found in the root bark of Tabernanthe iboga , a shrub native to Central West Africa. Origin, traditional use, and the language of “supplement” Ibogaine is an indole psychoactive alkaloid found in the root bark of Tabernanthe iboga . For centuries, indigenous cultures in Gabon, Cameroon, and Congo have used iboga in spiritual rituals and traditional medicine. This traditional healing context deserves respect, but it does not establish safety or effectiveness for modern addiction treatment. Western explorers documented the plant’s effects in the late nineteenth century, and ibogaine was first isolated in 1901. It belongs to a broader family of psychoactive alkaloids that includes compounds associated with psilocybin and DMT; the indole alkaloid classification helps describe its chemistry, not a clinical recommendation. Calling ibogaine a natural product can imply ordinary consumer safety. That is misleading. A plant extract can still have potent hallucinogenic properties, interact with medications, and create serious adverse effects. It is better understood as a high-risk psychoactive substan

Contact

Published channels